Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma

Qiwei Yang, Yufeng Tian, Shuqing Liu, Rana Zeine, Alexandre Chlenski, Helen R. Salwen, Jack Henkin, Susan L. Cohn

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

In the pediatric cancer neuroblastoma, clinically aggressive disease is associated with increased levels of angiogenesis stimulators and high vascular index. We and others have hypothesized that blocking angiogenesis may be effective treatment for this pediatric malignancy. However, little is known about the efficacy of antiangiogenic agents in pediatric malignancies. Recently, promising results have been reported in an adult phase I study of ABT-510, a peptide derivative of the natural angiogenic inhibitor thrombospondin-1. Histone deacetylase inhibitors, such as valproic acid (VPA), have also been shown to have antiangiogenic activity in several cancer models. In this study, we evaluated the effects of ABT-510 and VPA on neuroblastoma tumor growth and angiogenesis. Although only VPA was capable of blocking the proliferation of neuroblastoma cells and inducing neuroblastoma cell apoptosis in vitro, treatment with VPA or ABT-510 alone significantly suppressed the growth of neuroblastoma xenografts established from two different MYCN-amplified cell lines. Combination therapy more effectively inhibited the growth of small neuroblastoma xenografts than single-agent treatment, and in animals with large xenografts, total cessation of tumor growth was achieved with this treatment approach. The microvascular density was significantly reduced in the xenografts treated with combination therapy compared with controls or tumors treated with single agents. In addition, the number of structurally abnormal vessels was reduced, suggesting that these agents may "normalize" the tumor vasculature. Our results indicate that ABT-510 combined with VPA may be an effective antiangiogenic treatment strategy for children with high-risk neuroblastoma.

Original languageEnglish (US)
Pages (from-to)1716-1724
Number of pages9
JournalCancer Research
Volume67
Issue number4
DOIs
StatePublished - Feb 15 2007

Fingerprint

Thrombospondin 1
Valproic Acid
Neuroblastoma
Peptides
Heterografts
Neoplasms
Angiogenesis Inhibitors
Pediatrics
Growth
Therapeutics
Histone Deacetylase Inhibitors
NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt
Angiogenesis Inducing Agents
Blood Vessels
Cell Proliferation
Apoptosis
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. / Yang, Qiwei; Tian, Yufeng; Liu, Shuqing; Zeine, Rana; Chlenski, Alexandre; Salwen, Helen R.; Henkin, Jack; Cohn, Susan L.

In: Cancer Research, Vol. 67, No. 4, 15.02.2007, p. 1716-1724.

Research output: Contribution to journalArticle

Yang, Q, Tian, Y, Liu, S, Zeine, R, Chlenski, A, Salwen, HR, Henkin, J & Cohn, SL 2007, 'Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma', Cancer Research, vol. 67, no. 4, pp. 1716-1724. https://doi.org/10.1158/0008-5472.CAN-06-2595
Yang, Qiwei ; Tian, Yufeng ; Liu, Shuqing ; Zeine, Rana ; Chlenski, Alexandre ; Salwen, Helen R. ; Henkin, Jack ; Cohn, Susan L. / Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. In: Cancer Research. 2007 ; Vol. 67, No. 4. pp. 1716-1724.
@article{7057e9c76425459baabcfa408dc88e51,
title = "Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma",
abstract = "In the pediatric cancer neuroblastoma, clinically aggressive disease is associated with increased levels of angiogenesis stimulators and high vascular index. We and others have hypothesized that blocking angiogenesis may be effective treatment for this pediatric malignancy. However, little is known about the efficacy of antiangiogenic agents in pediatric malignancies. Recently, promising results have been reported in an adult phase I study of ABT-510, a peptide derivative of the natural angiogenic inhibitor thrombospondin-1. Histone deacetylase inhibitors, such as valproic acid (VPA), have also been shown to have antiangiogenic activity in several cancer models. In this study, we evaluated the effects of ABT-510 and VPA on neuroblastoma tumor growth and angiogenesis. Although only VPA was capable of blocking the proliferation of neuroblastoma cells and inducing neuroblastoma cell apoptosis in vitro, treatment with VPA or ABT-510 alone significantly suppressed the growth of neuroblastoma xenografts established from two different MYCN-amplified cell lines. Combination therapy more effectively inhibited the growth of small neuroblastoma xenografts than single-agent treatment, and in animals with large xenografts, total cessation of tumor growth was achieved with this treatment approach. The microvascular density was significantly reduced in the xenografts treated with combination therapy compared with controls or tumors treated with single agents. In addition, the number of structurally abnormal vessels was reduced, suggesting that these agents may {"}normalize{"} the tumor vasculature. Our results indicate that ABT-510 combined with VPA may be an effective antiangiogenic treatment strategy for children with high-risk neuroblastoma.",
author = "Qiwei Yang and Yufeng Tian and Shuqing Liu and Rana Zeine and Alexandre Chlenski and Salwen, {Helen R.} and Jack Henkin and Cohn, {Susan L.}",
year = "2007",
month = "2",
day = "15",
doi = "10.1158/0008-5472.CAN-06-2595",
language = "English (US)",
volume = "67",
pages = "1716--1724",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma

AU - Yang, Qiwei

AU - Tian, Yufeng

AU - Liu, Shuqing

AU - Zeine, Rana

AU - Chlenski, Alexandre

AU - Salwen, Helen R.

AU - Henkin, Jack

AU - Cohn, Susan L.

PY - 2007/2/15

Y1 - 2007/2/15

N2 - In the pediatric cancer neuroblastoma, clinically aggressive disease is associated with increased levels of angiogenesis stimulators and high vascular index. We and others have hypothesized that blocking angiogenesis may be effective treatment for this pediatric malignancy. However, little is known about the efficacy of antiangiogenic agents in pediatric malignancies. Recently, promising results have been reported in an adult phase I study of ABT-510, a peptide derivative of the natural angiogenic inhibitor thrombospondin-1. Histone deacetylase inhibitors, such as valproic acid (VPA), have also been shown to have antiangiogenic activity in several cancer models. In this study, we evaluated the effects of ABT-510 and VPA on neuroblastoma tumor growth and angiogenesis. Although only VPA was capable of blocking the proliferation of neuroblastoma cells and inducing neuroblastoma cell apoptosis in vitro, treatment with VPA or ABT-510 alone significantly suppressed the growth of neuroblastoma xenografts established from two different MYCN-amplified cell lines. Combination therapy more effectively inhibited the growth of small neuroblastoma xenografts than single-agent treatment, and in animals with large xenografts, total cessation of tumor growth was achieved with this treatment approach. The microvascular density was significantly reduced in the xenografts treated with combination therapy compared with controls or tumors treated with single agents. In addition, the number of structurally abnormal vessels was reduced, suggesting that these agents may "normalize" the tumor vasculature. Our results indicate that ABT-510 combined with VPA may be an effective antiangiogenic treatment strategy for children with high-risk neuroblastoma.

AB - In the pediatric cancer neuroblastoma, clinically aggressive disease is associated with increased levels of angiogenesis stimulators and high vascular index. We and others have hypothesized that blocking angiogenesis may be effective treatment for this pediatric malignancy. However, little is known about the efficacy of antiangiogenic agents in pediatric malignancies. Recently, promising results have been reported in an adult phase I study of ABT-510, a peptide derivative of the natural angiogenic inhibitor thrombospondin-1. Histone deacetylase inhibitors, such as valproic acid (VPA), have also been shown to have antiangiogenic activity in several cancer models. In this study, we evaluated the effects of ABT-510 and VPA on neuroblastoma tumor growth and angiogenesis. Although only VPA was capable of blocking the proliferation of neuroblastoma cells and inducing neuroblastoma cell apoptosis in vitro, treatment with VPA or ABT-510 alone significantly suppressed the growth of neuroblastoma xenografts established from two different MYCN-amplified cell lines. Combination therapy more effectively inhibited the growth of small neuroblastoma xenografts than single-agent treatment, and in animals with large xenografts, total cessation of tumor growth was achieved with this treatment approach. The microvascular density was significantly reduced in the xenografts treated with combination therapy compared with controls or tumors treated with single agents. In addition, the number of structurally abnormal vessels was reduced, suggesting that these agents may "normalize" the tumor vasculature. Our results indicate that ABT-510 combined with VPA may be an effective antiangiogenic treatment strategy for children with high-risk neuroblastoma.

UR - http://www.scopus.com/inward/record.url?scp=33847701595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847701595&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-2595

DO - 10.1158/0008-5472.CAN-06-2595

M3 - Article

VL - 67

SP - 1716

EP - 1724

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 4

ER -